UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET ...

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...

ProPhase Labs, Inc. (PRPH) shares ended the last trading session 8.5% higher at $8.42. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...

Prophase Labs ((PRPH)) has held its Q2 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and ...

ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered health ...

Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase ...

Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" ...

$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow ...

(RTTNews) - ProPhase Labs, Inc. (PRPH), a next-generation biotech and consumer products company, Thursday announced two key initiatives to strengthen its financial position and generate significant ...

ProPhase Labs (PRPH) and Advanced Biological Laboratories entered into a non-binding Letter of Intent regarding a proposed reverse merger transaction pursuant to which ABL would become the majority ...